Physician profile
Crispin Patrick Abbott
NPI 1063467926
$5,841.87
in general payments reported to CMS, 2019-2025
56 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $792 · 2022: $1,023 · 2023: $1,704 · 2024: $970 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.70 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $425.23 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $423.19 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $369.06 | 2022-2025 | |
| Pfizer INC. | $299.64 | 2021-2025 | |
| Astellas Pharma US INC | $245.81 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $199.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Karl Storz Endoscopy-America | $181.43 | 2021-2023 | Image1 S Connect |
| Glaxosmithkline, LLC. | $171.80 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $169.81 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $156.07 | 2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $136.86 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $89.14 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $89.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.93 | 2023-2025 | Breztri, Farxiga, Airsupra |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crispin Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.